Using a stem cell-derived therapeutic developed over more than a decade in Dr. David Gamm’s lab at UW-Madison, BlueRock Therapeutics has treated the first patient in a new Phase 1/2a clinical trial aimed at a group of …
Research News
Researchers find the tipping point at which compensatory measures in a diseased retinal circuit shift from beneficial to detrimental
A recent study by the Hoon lab published in Current Biology has uncovered new modes of retinal circuit compensation and adaptation in response to impairments seen in congenital stationary night blindness (CSNB). CSNB is a retinal disease …
McPherson ERI research featured on Chancellor’s new Research Moves Us Forward webpage
We’re pleased that Chancellor Mnookin has chosen to highlight research from MERI Director David Gamm’s lab to launch her new webpage on transformative, federally funded work happening right now at UW-Madison. You can read about …
Researchers ‘seq’ and find a way to make pig retinal cells to advance eye treatments
In a new study published in Stem Cell Reports, the Gamm Lab partnered with researchers at the Morgridge Institute for Research to develop lab-grown pig retinal organoids. They found that pig-derived photoreceptors shared many similarities with …
New research in Nature Communications from the lab of MERI PI Raunak Sinha!
Congratulations to Raunak Sinha, the McPherson ERI’s David and Nancy Walsh Family Professor, for his group’s latest publication in Nature Communications! In their article, Saha et al. show that light adaptation, our visual system’s ability …
Gamm Lab Discoveries Culminate in FDA Approval of a Clinical Trial for the Treatment of Inherited Photoreceptor Diseases
BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer AG, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for OpCT-001, …